Friday, December 6, 2013, New Orleans, LA, 12:30 PM – 3:30 PM (Central Time)

Consensus or Controversy? — Live: Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Non-Hodgkin Lymphoma (Part 1 of a 2-Part Series)

A Friday Satellite Symposium preceding the 55th ASH Annual Meeting

Hilton New Orleans Riverside Hotel
Two Poydras Street
New Orleans, LA 70140
Hotel Phone: (504) 561-0500

12:30 PM – 1:00 PM (Central Time) — Registration and Lunch
1:00 PM – 3:30 PM (Central Time) — Educational Meeting

Meeting Room: Grand Ballroom (1st Floor)

There is no registration fee for this event. However, registration is limited to clinicians in practice. Preregistration is advised as seating is limited.


Michele E Ghielmini, MD, PhD
Honorary Professor of Medicine
University of Bern
Medical Director
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland

Steven M Horwitz, MD
Assistant Attending
Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Brad S Kahl, MD
Skoronski Chair of Lymphoma Research
Associate Professor
University of Wisconsin School of
Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Madison, Wisconsin

Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and
University of British Columbia
Vancouver, British Columbia

Mitchell R Smith, MD, PhD
Director of Lymphoid Malignancies Program
at Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio


Neil Love, MD
Research To Practice
Miami, Florida

Module 1: Mantle-Cell Lymphoma (MCL) — Dr Kahl

Key Issues

  • What are the mechanisms of action (MOAs) and related side-effect profiles of BTK inhibitors, PI3 kinase inhibitors and Bcl-2-specific inhibitors? What is known about the efficacy of these agents in MCL and other B-cell neoplasms?
  • What is known about the comparative benefit of bortezomib and lenalidomide in terms of efficacy and tolerability in patients with relapsed/refractory disease, and how do you determine the sequence of these agents?

Module 2: Chronic Lymphocytic Leukemia (CLL) — Dr Smith

Key Issues

  • How does the MOA of obinutuzumab differ from that of rituximab, and what is known about the relative efficacy and tolerability of these 2 agents combined with chemotherapy?
  • What are the current and planned clinical trials designed to study combinations, maintenance and sequencing of new agents in CLL, including obinutuzumab, idelalisib and ibrutinib?

Module 3: T-Cell Lymphoma — Dr Horwitz

Key Issues

  • What is the range of “CD30 positivity” in T- and B-cell neoplasms, and does this correlate with the efficacy of brentuximab vedotin? For which patients with NHL do you order CD30 testing?
  • What is the relative spectrum of side effects and toxicities with romidepsin, pralatrexate, belinostat and vorinostat, and how are these agents being evaluated alone or in combination as up-front therapy?
  • What other novel agents are being evaluated in late-stage clinical trials that clinicians may likely be using in the next few years?

Module 4: Follicular Lymphoma (FL) — Dr Ghielmini

Key Issues

  • What is the relative efficacy and tolerability of BR (bendamustine/rituximab) versus R-CHOP in FL?
  • What is known about the use of rituximab monotherapy as up-front treatment in FL, and is there an optimal approach (eg, 4 or 8 cycles)?
  • What are the rationale for and available clinical trial data with the “R squared” regimen (lenalidomide/rituximab) in FL and other B-cell neoplasms?

Module 5: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn

Key Issues

  • What genomic analyses or biomarkers should be assessed by community-based oncologists, and how, if at all, should the results factor into clinical decision-making?
  • Does rituximab maintenance currently have a role after rituximab/chemotherapy for patients with DLBCL?
  • What data are currently available on the use of lenalidomide in DLBCL, and when, if at all, should it be used outside of a protocol setting?

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

Learning Objectives:

Upon completion of this activity, participants should be able to:

  • Appraise recent data on therapeutic advances and changing practice standards in NHL, including CLL, and integrate this information, when appropriate, into current clinical care.
  • Use emerging research information on novel prognostic and predictive clinical and molecular markers to aid in treatment decision-making for patients with NHL.
  • Develop an algorithm for the risk-stratified induction treatment of follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.
  • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
  • Recognize the role of romidepsin, pralatrexate, brentuximab vedotin and other novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma.
  • Recall new data with and assess ongoing trials of investigational agents demonstrating promising activity in NHL.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of this activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

This live activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hilton New Orleans Riverside Hotel
Two Poydras Street
New Orleans, LA 70140
Hotel Phone: (504) 561-0500

Meeting Room: Grand Ballroom (1st Floor)

The Hilton New Orleans Riverside hotel is located 2 blocks from the Ernest N Morial Convention Center, where the ASH Annual Meeting is taking place.

Thank you for your interest our program. At this time, preregistration is closed for this eventOnsite registration will be open starting at 12:30 PM (Eastern Time) on Friday, December 6. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (1st Floor) at the Hilton New Orleans Riverside Hotel (Two Poydras Street, New Orleans, LA 70140). 

If seats become available for the program, we will accept new registrations on a first come, first serve basis. Please note onsite registration does not guarantee participation in the session or meal service and seating is limited to clinicians in practice.

If you have any questions, please feel free to contact us via email at or call (800) 233-6153.  

This educational session has been approved by ASH as part of the Friday Satellite Symposia educational schedule and registration for this event is independent of registration for the ASH conference.